Access Industries
Access Industries is a private holding company and global investment firm based in New York. Founded in 1986, the firm deploys long-term capital across strategic equity, technology ventures, real estate, global media and entertainment, and biotechnology. Access pursues active, long-horizon investments, providing capital, board involvement and operational support to portfolio companies across sectors including media, creative technology, gaming, real estate, energy, chemicals and life sciences.
Industries
Nr. of Employees
medium (51-250)
Access Industries
New York, New York, United States
Services
Equity investments and control or minority stakes with multi-year capital commitments.
Board participation, strategic guidance, and coordination with management and external partners to drive enterprise value creation.
Seed to growth-stage investments in technology and life sciences companies, including co-leading rounds and providing scaled capital.
Selective allocations to externally managed public equity and hedge funds to complement direct investments.
Development, redevelopment and active management of hospitality, residential and commercial properties.
Co-incubation, seed and series financing for biotech companies and therapeutic platform development.
Equity investments and control or minority stakes with multi-year capital commitments.
Board participation, strategic guidance, and coordination with management and external partners to drive enterprise value creation.
Seed to growth-stage investments in technology and life sciences companies, including co-leading rounds and providing scaled capital.
Selective allocations to externally managed public equity and hedge funds to complement direct investments.
Development, redevelopment and active management of hospitality, residential and commercial properties.
Co-incubation, seed and series financing for biotech companies and therapeutic platform development.
Expertise Areas
- Investment management and long-term capital allocation
- Strategic equity and private equity investing
- Venture capital and technology growth investing
- Biotechnology investment and scientific evaluation
Key Technologies
- RNA interference (RNAi)
- Targeted protein degradation (PROTAC and related protein degraders)
- Oligonucleotide delivery technologies
- Radiopharmaceutical modalities
News & Updates
Sale of a major power generation portfolio in January 2025 following Access's 2018 acquisition with a consortium.
Landmark broadcast agreement announced in 2024 positioning a portfolio streaming business as a major sports rights holder.
Public listing in 2020 after multi-year repositioning and investment by the firm.
Launch of a dedicated biotechnology investment sector within the firm to invest across therapeutic modalities and stages.
Announcement that a Booker Prize-winning novel is being adapted to film with involvement from an affiliated production company.
Report on a triple-bill presentation at a production venue backed by investor partners, featuring digital and live programming.
Sale of a major power generation portfolio in January 2025 following Access's 2018 acquisition with a consortium.
Landmark broadcast agreement announced in 2024 positioning a portfolio streaming business as a major sports rights holder.
Public listing in 2020 after multi-year repositioning and investment by the firm.
Launch of a dedicated biotechnology investment sector within the firm to invest across therapeutic modalities and stages.
Announcement that a Booker Prize-winning novel is being adapted to film with involvement from an affiliated production company.
Report on a triple-bill presentation at a production venue backed by investor partners, featuring digital and live programming.